Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®

La Comisión Europea aprobó Ubeslo (obicetrapib 10 mg) y Evlarco (obicetrapib/ezetimiba 10 mg/10 mg), la primera autorización regulatoria mundial para obicetrapib, para hipercolesterolemia primaria. Los estudios fase 3 mostraron reducciones de LDL-C de hasta 40% con obicetrapib en monoterapia y de aproximadamente 50% con la combinación, con tolerabilidad comparable al placebo. Menarini comercializará en exclusiva los productos en Europa, mientras NewAmsterdam recibirá regalías escalonadas de dos dígitos y podría obtener hasta €833 millones en hitos clínicos, regulatorios y comerciales.

Analysis

For NAMS, European revenue recognition will lag the regulatory milestone materially: country-by-country pricing and reimbursement negotiations, rather than prescription demand, determine the next 6-12 months of royalty visibility. The fixed-dose combination could command better adherence and differentiation than standalone therapy, but its commercial ceiling is constrained by cheap generic ezetimibe and payer preference for sequential step therapy. Menarini absorbs launch execution risk, leaving NAMS with high incremental-margin royalty exposure but limited control over launch pace.

The key valuation rerating remains PREVAIL, not European availability. CETP inhibition carries a historical class-discount because prior agents failed to translate lipid changes into outcomes; a positive cardiovascular-outcomes readout would expand the addressable population and improve U.S. partnering leverage, while a neutral/safety-compromised result would sharply reduce terminal-value assumptions even if LDL lowering is sustained. Near-term enthusiasm may therefore be vulnerable to reimbursement delays or any indication that prescribers reserve obicetrapib only for narrow statin-intolerant or refractory cohorts.

Competitive pressure is asymmetric. AMGN's Repatha and NVS's Leqvio retain outcomes-data advantages in very-high-risk patients, but an effective daily oral option could pressure their use in patients unwilling to inject—particularly before PCSK9 reimbursement approval. ESPR is the most exposed listed comparator: an oral non-statin alternative with less LDL potency, although its established outcomes evidence is a meaningful defense. Consensus may overvalue the headline milestone if it capitalizes milestone payments before evidence of European net-price realization; conversely, it may underappreciate the strategic value of a successful outcomes trial to larger cardiometabolic franchises.

The immediate catalyst is reimbursement/list-price disclosure in major EU markets over 1-3 months; the investable fundamental catalyst is initial launch uptake and royalty guidance over 2-4 quarters. Falsify a constructive NAMS thesis if management cannot quantify a credible first-year launch cadence, if net pricing requires deep discounts versus injectables, or if PREVAIL timing slips. Monitor NVS/AMGN commentary on oral competition and ESPR prescription trends as early read-throughs on physician willingness to add another oral LDL agent.

Key Decisions for Investors

• Maintain or initiate a modest long NAMS only on post-approval consolidation rather than chase a headline gap; size as an event-driven biotech position with a 6-18 month horizon to PREVAIL. Upside requires reimbursement conversion plus outcomes validation, while downside is substantial if the market begins discounting delayed launch economics or a negative outcomes readout.
• Use a relative-value watch: long NAMS / short ESPR after confirming EU reimbursement breadth or first meaningful Menarini sales disclosure. The thesis is oral LDL share substitution, but do not execute without pricing data because ESPR's cardiovascular-outcomes evidence can sustain its premium; reassess if ESPR reports accelerating demand or improved payer access.
• Avoid shorting AMGN or NVS on this development alone. Their injectable franchises are protected by established outcomes data and entrenched reimbursement pathways; any displacement should emerge over 12-24 months and is most likely in lower-acuity, injection-averse patients rather than their core secondary-prevention populations.
• Set alerts for: major-market reimbursement decisions, NAMS royalty or launch guidance, PREVAIL event-rate/timing updates, and any safety signal. Treat the disclosed contingent milestone pool as zero in base-case valuation until the company specifies probability, timing, and commercial triggers.